59.82
-0.47 (-0.78%)
| Previous Close | 60.29 |
| Open | 60.29 |
| Volume | 172,076 |
| Avg. Volume (3M) | 356,743 |
| Market Cap | 2,079,678,208 |
| Price / Book | 3.39 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 4.64% |
| Current Ratio (MRQ) | 37.65 |
| Operating Cash Flow (TTM) | -101.70 M |
| Levered Free Cash Flow (TTM) | -66.74 M |
| Return on Assets (TTM) | -16.25% |
| Return on Equity (TTM) | -23.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Disc Medicine, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2025 | 2,384,456 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 118.00 (HC Wainwright & Co., 97.26%) | Buy |
| Median | 90.00 (50.45%) | |
| Low | 86.00 (Truist Securities, 43.77%) | Buy |
| Average | 98.00 (63.83%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 57.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 18 Aug 2025 | 90.00 (50.45%) | Buy | 58.84 |
| 03 Jul 2025 | 85.00 (42.09%) | Buy | 54.75 | |
| Truist Securities | 21 Jul 2025 | 86.00 (43.76%) | Buy | 59.38 |
| HC Wainwright & Co. | 03 Jul 2025 | 118.00 (97.26%) | Buy | 54.75 |
| 17 Jun 2025 | 118.00 (97.26%) | Buy | 50.05 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Disc Medicine to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 21 Jul 2025 | Announcement | Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 |
| 14 Jul 2025 | Announcement | Disc Medicine Appoints Nadim Ahmed to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |